Frontlight ResearchEarly access
Ovarian cancer trials in United Kingdom
64 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Cambridge, Glasgow, Scotland, London, Sutton
- Age
- 18 years to 130 years
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- London, Newcastle upon Tyne
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - No phaseTaking peopleInnovative Ovarian Cancer Biomarker Assays
- Where
- London
- Age
- 35 years and over
- People
- 2,080 worldwide
- Run by
- National and Kapodistrian University of Athens
See details and how to joinNCT07693894 - Phase 1/2Taking peopleStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Where
- London, Manchester, Oxford, Sutton
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Cambridge, Dundee, London, Manchester
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - Phase 1/2Taking peopleBI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- Where
- Birmingham, Leicester, London, Manchester, Southampton
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- BioInvent International AB
See details and how to joinNCT04752826 · EU 2023-509847-29-00 - Phase 2Taking peopleA Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- London, Manchester Greater
- Age
- 18 years to 99 years
- People
- 160 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07023627 · EU 2025-521513-14-00 - Phase 1Taking peopleA Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
- Where
- London, Manchester
- Age
- 18 years to 75 years
- People
- 9
- Run by
- Zelluna Immunotherapy AS
See details and how to joinNCT07613723 - Phase 3Taking peopleActive Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- Where
- Broomhall, Cambridge, Edinburgh, Glasgow, London, Manchester, Newcastle, Newcastle upon Tyne, Oxford, Sheffield, West Yorkshire
- People
- 1,780 worldwide
- Run by
- Children's Oncology Group
See details and how to joinNCT03067181 - Phase 1/2Taking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - Phase 2/3Taking peopleDETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
- Where
- Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Leicester, Liverpool, London, Manchester, Metropolitan Borough of Wirral, Newcastle, Oxford, Sheffield, Southampton, Sutton
- Age
- 1 year and over
- People
- 30
- Run by
- Cancer Research UK
See details and how to joinNCT07440290 - Phase 1/2Taking peopleStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Where
- Glasgow, London, Manchester, Newcastle upon Tyne, Oxford
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT05985655 - No phaseTaking peopleClinical Pre-screening Protocol for Ovarian Cancer
- Where
- Glasgow, London
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Allarity Therapeutics
See details and how to joinNCT03877796 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- London, Manchester
- Age
- 8 years and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - Phase 1Taking peopleStudy of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Where
- London, Manchester, Newcastle upon Tyne
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- MOMA Therapeutics
See details and how to joinNCT06545942 - Phase 3Taking peopleAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London, Nottingham, Sutton, Swansea
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - Phase 1Taking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Birmingham, London, Sutton
- Age
- 18 years and over
- People
- 1,006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - No phaseTaking peopleClinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
- Where
- London
- Age
- 18 years and over
- People
- 100
- Run by
- Royal Marsden NHS Foundation Trust
See details and how to joinNCT07673861 - Phase 1Taking peopleStudy of STP938 (Dencatistat) in Advanced Solid Tumours
- Where
- Glasgow, London, Manchester
- Age
- 18 years and over
- People
- 70 worldwide
- Run by
- Step Pharma, SAS
See details and how to joinNCT06297525 · EU 2024-512375-12-00 - Phase 1/2WithdrawnA Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Where
- Belfast, Cardiff, Glasgow, London, Manchester, Northwood, Preston, Sutton
- Age
- 18 years and over
- People
- 182 worldwide
- Run by
- Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00 - Phase 2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
- Where
- Cambridge, Exeter, London
- Age
- 18 years and over
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT06682988 · EU 2024-517184-23-00 - Phase 2Taking peopleA Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
- Where
- London, Southampton
- Age
- 18 years and over
- People
- 114 worldwide
- Run by
- Oncoinvent Solutions AS
See details and how to joinNCT06504147 - Phase 1/2Taking peopleA Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
- Where
- London, Manchester, Newcastle upon Tyne, Southampton
- Age
- 18 years and over
- People
- 167
- Run by
- Cancer Research UK
See details and how to joinNCT06380816 - Phase 1/2Taking peopleTrial of THEO-260 in Ovarian Cancer Patients
- Where
- Glasgow, London, Oxford
- Age
- 18 years and over
- People
- 44 worldwide
- Run by
- Theolytics Limited
See details and how to joinNCT06618235 · EU 2024-511236-27-00 - Phase 1Taking peopleA Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
- Where
- Bristol, Edinburgh, Leeds, London, Southampton
- Age
- 18 years and over
- People
- 45
- Run by
- Epsilogen Ltd
See details and how to joinNCT06547840